Oxaliplatin with Fluoropyrimidine/Bevacizumab for Initial Therapy for Unresectable mCRC in Older Patients
The authors did a crude vulnerability survey (VES-13) annd admit a more thorough GA would be helpful. Still, this helps inform conversation in the clinic.
Another successful study focused on older adults with cancer. In this case, ‘start low go slow’ is a reasonable strategy
–no compromise in efficacy
–better tolerability
–no difference in ability to receive 2nd line therapy
Would love to see differences in ability to maintain function (IADLS) and unplanned acute care received (ED, hospitalizations) which I suspect would be better in the less intensive treatment arm
Authors: Atsuo Takashima, Tetsuya Hamaguchi, Junki Mizusawa, Fumio Nagashima, Masahiko Ando, Hitoshi Ojima, Tadamichi Denda, Jun Watanabe, Katsunori Shinozaki, Hideo Baba, Masako Asayama, SeijiHasegawa, Toshiki Masuishi, Ken Nakata, Shunsuke Tsukamoto, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yukihide Kanemitsu, and Yasuhiro Shimada, on behalf of Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG)
Source: Ramy Sedhom/X
For more posts by Ramy Sedhom, visit oncodaily.com
Ramy Sedhom holds positions as Assistant Professor of Hematology and Oncology at Perelman School of Medicine and Director of Medical Oncology and Palliative Care at Penn Medicine’s Princeton Medical Center.
His work focuses on palliative care integration, geriatric assessment, psycho-oncology, caregiver distress, and remote patient monitoring, with publications in leading journals. Nationally, he contributes to guideline panels and committees, including the NCCN Guideline Panel for Older Adults with Cancer, and leadership roles within ASCO.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023